Richard Scott Struthers Crinetics Pharmaceuticals, Inc. (CRNX) insider trading activity

Richard Scott Struthers is President & CEO of Crinetics Pharmaceuticals, Inc.. Currently has a direct ownership of 346,485 shares of CRNX, which is worth approximately $12 Million. The most recent transaction as insider was on Feb 20, 2025, when has been sold 89,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 346K

34.57% 3M change

86.76% 12M change

Total Value Held $12 Million

Richard Scott Struthers Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 20 2025	BUY Grant, award, or other acquisition	-	89,000 Added 20.44%	346,485 Common Stock
May 08 2024	SELL Open market or private sale	$5,307,931 $49.4 p/Share	107,448 Reduced 29.44%	257,485 Common Stock
May 08 2024	BUY Exercise of conversion of derivative security	$997,117 $9.28 p/Share	107,448 Added 22.75%	364,933 Common Stock
Apr 18 2024	SELL Bona fide gift	-	350 Reduced 0.14%	257,485 Common Stock
Apr 15 2024	BUY Exercise of conversion of derivative security	$38,200 $1.91 p/Share	20,000 Added 7.2%	257,835 Common Stock
Apr 04 2024	SELL Open market or private sale	$2,013,560 $49.17 p/Share	40,951 Reduced 14.69%	237,835 Common Stock
Apr 04 2024	BUY Exercise of conversion of derivative security	$380,025 $9.28 p/Share	40,951 Added 12.81%	278,786 Common Stock
Mar 18 2024	SELL Payment of exercise price or tax liability	$483,882 $38.14 p/Share	12,687 Reduced 5.06%	237,835 Common Stock
Mar 04 2024	BUY Grant, award, or other acquisition	-	65,000 Added 20.6%	250,522 Common Stock
Nov 09 2023	BUY Exercise of conversion of derivative security	$95,500 $1.91 p/Share	50,000 Added 21.23%	185,522 Common Stock
Nov 03 2023	SELL Open market or private sale	$6,083,945 $30.56 p/Share	199,082 Reduced 59.5%	135,522 Common Stock
Nov 03 2023	BUY Exercise of conversion of derivative security	$1,847,480 $9.28 p/Share	199,082 Added 37.3%	334,604 Common Stock
Nov 02 2023	SELL Open market or private sale	$27,494 $29.95 p/Share	918 Reduced 0.67%	135,522 Common Stock
Nov 02 2023	BUY Exercise of conversion of derivative security	$8,519 $9.28 p/Share	918 Added 0.67%	136,440 Common Stock
Aug 14 2023	BUY Exercise of conversion of derivative security	$19,100 $1.91 p/Share	10,000 Added 6.87%	135,522 Common Stock
Mar 16 2023	SELL Payment of exercise price or tax liability	$79,231 $17.12 p/Share	4,628 Reduced 3.56%	125,522 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	61,650 Added 32.14%	130,150 Common Stock
Oct 12 2022	BUY Exercise of conversion of derivative security	$21,201 $1.91 p/Share	11,100 Added 13.94%	68,500 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	-	53,400 Added 48.19%	57,400 Common Stock
Dec 03 2020	BUY Open market or private purchase	$52,400 $13.1 p/Share	4,000 Added 50.0%	4,000 Common Stock
May 08 2019	SELL Bona fide gift	-	1,215,805 Reduced 100.0%	0 Common Stock

RSS

Richard Scott Struthers

President & CEO

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRNX shares.

Notify only if

Value

Insider Trading

Get notified when an Crinetics Pharmaceuticals, Inc. insider buys or sells CRNX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Crinetics Pharmaceuticals, Inc.

Track Activities on CRNX

Account